Join Growin Stock Community!

Palisade bio, inc.PALI.US Overview

US StockHealthcare
(No presentation for PALI)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

PALI AI Insights

PALI Overall Performance

PALI AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

PALI Recent Performance

-0.28%

Palisade bio, inc.

0.05%

Avg of Sector

-0.31%

S&P500

PALI PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

PALI Key Information

PALI Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

PALI Profile

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.

Price of PALI

PALI FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

PALI Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.08
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
14.03
PB Ratio
82.27
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.08
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
14.03
PB Ratio
82.27
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is PALI's latest earnings report released?

    The most recent financial report for Palisade bio, inc. (PALI) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating PALI's short-term business performance and financial health. For the latest updates on PALI's earnings releases, visit this page regularly.

  • How much cash does PALI have?

    At the end of the period, Palisade bio, inc. (PALI) held Total Cash and Cash Equivalents of 5.25M, accounting for 0.75 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is PALI's EPS continuing to grow?

    According to the past four quarterly reports, Palisade bio, inc. (PALI)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.38. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of PALI?

    Palisade bio, inc. (PALI)'s Free Cash Flow (FCF) for the period is -3.55M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 13.41% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of PALI?

    The latest valuation data shows Palisade bio, inc. (PALI) has a Price-To-Earnings (PE) ratio of -23.49 and a Price/Earnings-To-Growth (PEG) ratio of 0.02. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.